Skip to main content
    X

    Xencor Inc (XNCR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $35.40
    -1.69 (-4.56%)

    Market Cap: $2.78B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Xencor Inc (XNCR) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Xencor are Xenon Pharmaceuticals (XENE), Celldex Therapeutics (CLDX) and Zenas BioPharma, Inc. Common Stock (ZBIO). By market cap, Xencor ranks 7th of the 13 companies on this page; Xenon Pharmaceuticals (XENE) is the largest at $3.98B. The median P/E of the 3 companies with a P/E is 89.8x.

    Peer Comparison

    XNCR's ROIC of -17.3% is above the peer median of -65.4%, and its revenue growth of 454.9% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Xencor (XNCR)$2.78BN/A13.5x-58.8%-17.3%454.9%0.00%
    Xenon Pharmaceuticals Inc (XENE)$3.98BN/AN/A0.0%N/A-100.0%0.00%
    Celldex Therapeutics Inc (CLDX)$2.26BN/AN/A0.0%N/A-97.0%0.00%
    Zenas BioPharma, Inc. Common Stock (ZBIO)$1.90BN/A168.0x0.0%-104.3%-100.0%0.00%
    MBX Biosciences, Inc. Common Stock (MBX)$2.78BN/AN/A0.0%N/A0.0%0.00%
    Celcuity LLC (CELC)$3.15BN/AN/A0.0%-25.2%0.0%0.00%
    Vericel Corp Ord (VCEL)$2.91B89.8x9.1x10.3%N/A26.5%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Iovance Biotherapeutics Inc (IOVA)$3.59BN/A9.1x-58.2%N/A80.1%0.00%
    Legend Biotech Corp (LEGN)$3.39B266.5x2.3x-0.0%N/A32.0%0.00%
    Replimune Group Inc (REPL)$2.08BN/AN/A0.0%-65.4%0.0%0.00%
    Telix Pharmaceuticals Limited (TLX)$3.14BN/A5.3x3.8%-0.7%22.3%0.00%
    Arcus Biosciences Inc (RCUS)$2.51BN/A21.5x0.0%-75.9%-65.4%0.00%
    Peer median$2.84B89.8x9.1x0.0%-65.4%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Xencor, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Xenon Pharmaceuticals Inc (XENE)
    Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders...
    XENE competitors
    Celldex Therapeutics Inc (CLDX)
    Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment...
    CLDX competitors
    Zenas BioPharma, Inc. Common Stock (ZBIO)
    Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based...
    ZBIO competitors
    MBX Biosciences, Inc. Common Stock (MBX)
    MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment...
    MBX competitors
    Celcuity LLC (CELC)
    Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States.
    CELC competitors
    Vericel Corp Ord (VCEL)
    Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures...
    VCEL competitors
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Iovance Biotherapeutics Inc (IOVA)
    Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness...
    IOVA competitors
    Legend Biotech Corp (LEGN)
    Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology...
    LEGN competitors
    Replimune Group Inc (REPL)
    Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
    REPL competitors
    Telix Pharmaceuticals Limited (TLX)
    Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic...
    Arcus Biosciences Inc (RCUS)
    Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States.
    RCUS competitors

    Frequently Asked Questions About XNCR

    Who are Xencor's main competitors?

    The companies most similar to Xencor include Xenon Pharmaceuticals (XENE), Celldex Therapeutics (CLDX), Zenas BioPharma, Inc. Common Stock (ZBIO), MBX Biosciences, Inc. Common Stock (MBX) and Celcuity LLC (CELC), listed from the closest match.

    Who is Xencor's biggest competitor?

    Xenon Pharmaceuticals (XENE) is both the largest of the similar companies at $3.98B and the closest match by business profile, size, sector and industry.

    How does XNCR stock compare with its competitors?

    XNCR's P/S is 13.5x against a peer median of 9.1x; its net margin is -58.8% against a peer median of 0.0%.

    Which of Xencor's competitors pays a higher dividend?

    Xencor pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Xencor bigger than its competitors?

    No. Xencor is 7th by market cap among the 13 companies on this page; the largest is Xenon Pharmaceuticals (XENE) at $3.98B.